I am trying to find a way to not be very excited about Nadar's comment that "The head of the FDA" asked us to submit our data as soon as it is unblinded, before we do any analysis.

I think this has to put to bed the question of whether or not the FDA has an inclination as to our efficacy. I dont want to get ahead of myself, but I cannot see any other possibility.

I think this is an extraordinarily good sign.

Just my opinion though.